Large multi-center Phase 3 human clinical trials testing efficacy, absolute risk reduction, and adverse-event rates against placebo or active gold-standard comparators. Every study summary reports the trial design, participant sample size (N), primary outcome highlight, and direct link to the formal NCBI PubMed or federal record.
The Plain-English Receipt: Only 1.2% of prediabetic adults on Tirzepatide progressed to Type 2 diabetes over 3.4 years vs. 19.3% on placebo (Absolute Risk Reduction = 18.1% • Number Needed to Treat = 6).
Our limited analysis found that a reactive NGT should be considered for most HNC patients undergoing RT.
We investigate settings in which the combined penalty is beneficial compared to global lasso regularization.
Despite the high discontinuation rate in the CHT arm, OS benefit with EVP remains robust.
Carotegrast methyl appears most effective in patients with moderately active ulcerative colitis with low disease activity, with week 2 and beyond as an appropriate time point for assessing efficacy.
Infusion-related TEAEs were more frequent in ADA-positive patients, although the sample size was small.
AD symptom improvement was maintained up to Week 200 with baricitinib 4 mg.
Among participants without an exacerbation history in the prior 12 months, FPC identified those at higher exacerbation risk.
Data from this large trial suggest that ARCT-154 is safe and well tolerated.
As a result of the coronavirus disease 2019 pandemic, asthma exacerbation rates were much lower than expected, contributing to the primary endpoint not being met.
The microbiota-gut-brain axis is posited to modulate health-related quality of life, microbiome, and metabolome changes through immune, gastrointestinal, and central nervous system functions in patients with recurrent C.
This study provides support for acne treatment with CAB in ethnically diverse populations.
The test freeze-dried live attenuated VarV demonstrated good immunogenicity and higher safety compared to the active control vaccine in healthy participants aged 13-55 years.
These analyses suggest that elevated post-nephrectomy plasma KIM-1 level and kinetics are prognostic, supporting the hypothesis that KIM-1 is a biomarker for minimal residual disease in RCC.
Tafamidis treatment reduced the risk of mortality and hospitalization in patients with NAC stages I/II ATTR-CM, with favourable trends at stage III.
Conclusions: These findings suggest that self-compassion may play a critical role in the therapeutic effects of MDMA-AT.
Results from the population PK model and E-R analyses reinforce the evidence base for valbenazine efficacy in reducing chorea severity, as demonstrated by the notable decrease in TMC scores compared to baseline.
The freeze-dried live attenuated VarV developed by Beijing Minhai Biotechnology Co.
Kidney function did not impact staying on track with medication, quantifiable CMV DNAemia, or prophylaxis discontinuation in the letermovir group; however, staying on track with medication was lower, and quantifiable CMV...
This study utilizes data from a large clinical trial to establish a method with high specificity for exploring clonal engraftment from microbiota-based treatments to facilitate future how the body absorbs the medicine and how...
Weight loss resulting from lifestyle interventions is associated with reductions in plasma BCAA concentrations.
This study supports the use of MenACYW-TT in infants aged 6 weeks (42 days) or older.
COPDPredict™ failed to show a reduction in severe AECOPD events resulting in hospitalisations, although the number of admissions per participant was lower among users.
CONCLUSION: Our composite biomarker score showed a moderate cross-sectional correlation with mRSS and potentially complement mRSS in the assessment of skin activity.
Due to the underpowered nature of the trial and the observed trend, it cannot be ruled out that using AI to prevent invasive breast cancer could be effective for BRCA1/2 carriers overall, or for specific subgroups within a...
Further studies are needed to improve PPH prevention in VWD.
Both QIVs elicit significant increases in antibody titers 28 days after vaccination; Sinovac-QIV induces 9-10-fold increases in geometric mean titers, while Vaxigrip-Tetra™ elicits 7-8-fold increases (p + and CD8 + T cell...
No significant differences in treatment response were observed across racial/ethnic groups.
Despite meeting their primary endpoints (PFS), neither final OS analysis of TOURMALINE-MM3/-MM4 showed statistically significant differences between fixed-duration ixazomib maintenance.
Mixing lidocaine-epinephrine with ropivacaine significantly shortened the duration of pain-relieving by up to 5 h without affecting the sensory onset time.
This post hoc analysis of MEAD study data showed that DEX treatment may potentially have a positive impact on diabetic retinopathy by reducing disease severity and slowing progression in patients with diabetic retinopathy with...
Traditional health headlines often exaggerate findings by reporting only Relative Risk Reduction—for example, claiming a drug cuts risk by 50% when the event rate dropped from 2% to 1% (an Absolute Risk Reduction of just 1.0 percentage point, meaning 100 patients must take the drug for 1 person to benefit, or NNT = 100). On dotMD, every flagship study breakdown reports both Relative Risk and Absolute Risk alongside the exact sample size (N) and trial duration.
Every study on dotMD displays its exact Study Design Tier at the top of the card (Phase 3 Randomized Trial, Randomized Controlled Trial, Meta-Analysis & Systematic Review, Multi-Trial Clinical Evidence Synthesis, Journal Watch Cohort, or FDA Safety Alert) along with the human participant count (N). Preclinical mouse or cell-culture data is never presented as human clinical proof.
Arbitrary 0-to-100 rigor scores obscure what actually makes a study trustworthy. Instead of synthetic scores, dotMD surfaces the verifiable primary evidence signals: exact NCBI PubMed IDs (PMID), ClinicalTrials.gov registration numbers (NCT), double-blind vs. crossover design, sample size (N), p-values / Hazard Ratios, and study limitations.
Medical research is only useful if you can act on it safely with your clinician. Every flagship research synthesis links directly to the parent Condition diagnostic cutoff guide, the Medication FDA DailyMed & CMS NADAC wholesale price ledger, the Supplement elemental weight decoder, and our High-CPT-Volume Specialist Directory.
